Home › Rating Schedule › Hemic and Lymphatic Systems
Diagnostic Code 7719: Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia)
Hemic and Lymphatic Systems · 38 CFR §4.117 · All codes in this system
| Evaluation criteria | Rating |
|---|---|
| Requiring peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy treatment | 100% |
| Requiring intermittent myelosuppressive therapy, or molecularly targeted therapy with tyrosine kinase inhibitors, or interferon treatment when not in apparent remission | 60% |
| In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors | 30% |
| Note (1): If the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703 | |
| Note (2): A 100 percent evaluation shall be assigned as of the date of hospital admission for peripheral blood or bone marrow stem cell transplant; or during the period of treatment with chemotherapy (including myelosuppressants). Six months following hospital discharge or, in the case of chemotherapy treatment, six months after completion of treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of ยง 3.105 of this chapter | |
Use this rating
Open the combined ratings calculator with this percentage already entered, then add your other rated conditions:
100% in the calculator 60% in the calculator 30% in the calculator
Source: eCFR Title 38, 38 CFR §4.117, current as of 2026-11-05. Criteria text is the regulatory text, reproduced verbatim for reference; it is not legal advice.